Vaccination and the evolutionary ecology of human papillomavirus

被引：21

作者：

Poolman, Eric M. ^{[1
]}

Elbasha, Elarnin H. ^{[2
]}

Galvani, Alison P. ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA

[2] Merck Res Labs, UG1C 60, N Wales, PA 19454 USA

来源：

VACCINE | 2008年 / 26卷

关键词：

human papillomavirus; vaccine; evolution;

D O I：

10.1016/j.vaccine.2008.04.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

New and upcoming vaccines provide protection against types 16 and 18 of human papillomavirus (HPV), which are responsible for an estimated 70% of all cervical cancers. One vaccine also protects against HPV types 6 and 11, which cause more than 90% of genital warts. We use a mathematical model of HPV transmission and immunity to explore the effect of vaccination on the evolution of HPV types. If vaccination provides cross-immunity at least equal to that of natural infection, it may contract the niche space available to other HPV types a million-fold. If natural infection provides greater cross-immunity than vaccination, vaccination may expand available niche space up to 470-fold. The balance of epidemiologic data suggests vaccination will reduce the available niche space. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：C25 / C30

页数：6

共 39 条

[1] Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses [J].

Barnabas, Ruanne V. ;

Laukkanen, Paivi ;

Koskela, Pentti ;

Kontula, Osmo ;

Lehtinen, Matti ;

Garnett, Geoff P. .

PLOS MEDICINE, 2006, 3 (05) :624-632

[2] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].

BOSCH, FX ;

MANOS, MM ;

MUNOZ, N ;

SHERMAN, M ;

JANSEN, AM ;

PETO, J ;

SCHIFFMAN, MH ;

MORENO, V ;

KURMAN, R ;

SHAH, KV ;

ALIHONOU, E ;

BAYO, S ;

MOKHTAR, HC ;

CHICAREON, S ;

DAUDT, A ;

DELOSRIOS, E ;

GHADIRIAN, P ;

KITINYA, JN ;

KOULIBALY, M ;

NGELANGEL, C ;

TINTORE, LMP ;

RIOSDALENZ, JL ;

SARJADI ;

SCHNEIDER, A ;

TAFUR, L ;

TEYSSIE, AR ;

ROLON, PA ;

TORROELLA, M ;

TAPIA, AV ;

WABINGA, HR ;

ZATONSKI, W ;

SYLLA, B ;

VIZCAINO, P ;

MAGNIN, D ;

KALDOR, J ;

GREER, C ;

WHEELER, C .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802

[3] Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections [J].

Chaturvedi, AK ;

Myers, L ;

Hammons, AF ;

Clark, RA ;

Dunlap, K ;

Kissinger, PJ ;

Hagensee, ME .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (10) :2439-2445

[4] ANTIBODY-MEDIATED NEUTRALIZATION INVIVO OF INFECTIOUS PAPILLOMAVIRUSES [J].

CHRISTENSEN, ND ;

KREIDER, JW .

JOURNAL OF VIROLOGY, 1990, 64 (07) :3151-3156

[5] Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer [J].

Combita, AL ;

Bravo, MM ;

Touzé, A ;

Orozco, O ;

Coursaget, P .

INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (06) :796-803

[6] Prevalence of HPV infection among females in the United States [J].

Dunne, Eileen F. ;

Unger, Elizabeth R. ;

Sternberg, Maya ;

McQuillan, Geraldine ;

Swan, David C. ;

Patel, Sonya S. ;

Markowitz, Lauri E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (08) :813-819

[7] Vaccination against multiple HPV types [J].

Elbasha, EH ;

Galvani, AP .

MATHEMATICAL BIOSCIENCES, 2005, 197 (01) :88-117

[8] Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine [J].

Emeny, RT ;

Wheeler, CM ;

Jansen, KU ;

Hunt, WC ;

Fu, TM ;

Smith, JF ;

MacMullen, S ;

Esser, MT ;

Paliard, X .

JOURNAL OF VIROLOGY, 2002, 76 (15) :7832-7842

[9] Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer [J].

Franco, EL ;

Villa, LL ;

Sobrinho, JP ;

Prado, JM ;

Rousseau, MC ;

Désy, M ;

Rohan, TE .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (05) :1415-1423

[10] Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine [J].

Fraser, Christophe ;

Tomassini, Joanne E. ;

Xi, Liwen ;

Golm, Greg ;

Watson, Michael ;

Giuliano, Anna R. ;

Barr, Eliav ;

Ault, Kevin A. .

VACCINE, 2007, 25 (21) :4324-4333

← 1 2 3 4 →